These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23378927)

  • 1. Novel genetically-humanized mouse model established to evaluate efficacy of therapeutic agents to human interleukin-6 receptor.
    Ueda O; Tateishi H; Higuchi Y; Fujii E; Kato A; Kawase Y; Wada NA; Tachibe T; Kakefuda M; Goto C; Kawaharada M; Shimaoka S; Hattori K; Jishage K
    Sci Rep; 2013; 3():1196. PubMed ID: 23378927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].
    Ohsugi Y; Tsuchimoto N
    Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):419-25. PubMed ID: 16462093
    [No Abstract]   [Full Text] [Related]  

  • 3. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases.
    Nagao A; Nakazawa S; Hanabusa H
    J Hematol Oncol; 2014 Jan; 7():10. PubMed ID: 24438824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
    Matsuyama M; Suzuki T; Tsuboi H; Ito S; Mamura M; Goto D; Matsumoto I; Tsutsumi A; Sumida T
    Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 in idiopathic multicentric Castleman's disease after long-term tocilizumab.
    Akiyama M; Yasuoka H; Takeuchi T
    Ann Hematol; 2017 Dec; 96(12):2117-2119. PubMed ID: 28861599
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-interleukin 6 receptor antibody treatment in rheumatic disease.
    Nishimoto N; Kishimoto T; Yoshizaki K
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i21-7. PubMed ID: 11053081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunotherapy using IL-6 receptor as the target].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):399-404. PubMed ID: 18974624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
    Nishimoto N; Terao K; Mima T; Nakahara H; Takagi N; Kakehi T
    Blood; 2008 Nov; 112(10):3959-64. PubMed ID: 18784373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
    ; Swerdlow DI; Holmes MV; Kuchenbaecker KB; Engmann JE; Shah T; Sofat R; Guo Y; Chung C; Peasey A; Pfister R; Mooijaart SP; Ireland HA; Leusink M; Langenberg C; Li KW; Palmen J; Howard P; Cooper JA; Drenos F; Hardy J; Nalls MA; Li YR; Lowe G; Stewart M; Bielinski SJ; Peto J; Timpson NJ; Gallacher J; Dunlop M; Houlston R; Tomlinson I; Tzoulaki I; Luan J; Boer JM; Forouhi NG; Onland-Moret NC; van der Schouw YT; Schnabel RB; Hubacek JA; Kubinova R; Baceviciene M; Tamosiunas A; Pajak A; Topor-Madry R; Malyutina S; Baldassarre D; Sennblad B; Tremoli E; de Faire U; Ferrucci L; Bandenelli S; Tanaka T; Meschia JF; Singleton A; Navis G; Mateo Leach I; Bakker SJ; Gansevoort RT; Ford I; Epstein SE; Burnett MS; Devaney JM; Jukema JW; Westendorp RG; Jan de Borst G; van der Graaf Y; de Jong PA; Mailand-van der Zee AH; Klungel OH; de Boer A; Doevendans PA; Stephens JW; Eaton CB; Robinson JG; Manson JE; Fowkes FG; Frayling TM; Price JF; Whincup PH; Morris RW; Lawlor DA; Smith GD; Ben-Shlomo Y; Redline S; Lange LA; Kumari M; Wareham NJ; Verschuren WM; Benjamin EJ; Whittaker JC; Hamsten A; Dudbridge F; Delaney JA; Wong A; Kuh D; Hardy R; Castillo BA; Connolly JJ; van der Harst P; Brunner EJ; Marmot MG; Wassel CL; Humphries SE; Talmud PJ; Kivimaki M; Asselbergs FW; Voevoda M; Bobak M; Pikhart H; Wilson JG; Hakonarson H; Reiner AP; Keating BJ; Sattar N; Hingorani AD; Casas JP
    Lancet; 2012 Mar; 379(9822):1214-24. PubMed ID: 22421340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of a mesangial proliferative glomerulonephritis with interstitial nephritis associated with Castleman's disease by an anti-interleukin-6 receptor antibody (tocilizumab).
    Otani N; Morishita Y; Oh I; Saito O; Takemoto F; Muto S; Kusano E
    Intern Med; 2012; 51(11):1375-8. PubMed ID: 22687845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman's disease.
    Ebisawa K; Masamoto Y; Tokushige J; Nishi H; Honda K; Hinata M; Toyama K; Nangaku M; Kurokawa M
    Ann Hematol; 2019 Aug; 98(8):1995-1997. PubMed ID: 30761408
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
    Kawabata H; Tomosugi N; Kanda J; Tanaka Y; Yoshizaki K; Uchiyama T
    Haematologica; 2007 Jun; 92(6):857-8. PubMed ID: 17550864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody.
    Kawabata H; Kotani S; Matsumura Y; Kondo T; Katsurada T; Haga H; Kadowaki N; Takaori-Kondo A
    Intern Med; 2013; 52(13):1503-7. PubMed ID: 23812199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of IL-6 and Development of Anti-IL-6R Antibody.
    Kishimoto T
    Keio J Med; 2019; 68(4):96. PubMed ID: 31875623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-interleukin-6 receptor antibody therapy--from bedside to bench].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2006 Oct; 29(5):289-94. PubMed ID: 17075187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Higuchi T; Nakanishi T; Takada K; Matsumoto M; Okada M; Horikoshi H; Suzuki K
    J Korean Med Sci; 2010 Sep; 25(9):1364-7. PubMed ID: 20808682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL6 receptor blockade preserves articular cartilage and increases bone volume following ischemic osteonecrosis in immature mice.
    Kamiya N; Kuroyanagi G; Aruwajoye O; Kim HKW
    Osteoarthritis Cartilage; 2019 Feb; 27(2):326-335. PubMed ID: 30404032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of tocilizumab-refractory idiopathic multicentric Castleman's disease successfully treated with sirolimus.
    Sumiyoshi R; Koga T; Furukawa K; Umeda M; Yamamoto K; Mori R; Kawakami A
    Clin Immunol; 2021 Dec; 233():108887. PubMed ID: 34798240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome.
    Bensadoun JC; de Almeida LP; Dréano M; Aebischer P; Déglon N
    Eur J Neurosci; 2001 Dec; 14(11):1753-61. PubMed ID: 11860469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Interleukin 6 signaling receptors in carotid atherosclerosis.
    Ziegler L; Lundqvist J; Dreij K; Wallén H; de Faire U; Paulsson-Berne G; Hedin U; Matic L; Gigante B
    Vasc Med; 2021 Feb; 26(1):3-10. PubMed ID: 33350884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.